We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

78 hedge funds and large institutions have $273M invested in Adamas Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 28 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 18

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0% less capital invested

Capital invested by funds: $273M → $273M (-$47.7K)

9% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 11

4% less funds holding

Funds holding: 81 → 78 (-3)

Holders
78
Holders Change
-3
Holders Change %
-3.7%
% of All Funds
1.95%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
10
Increased
28
Reduced
18
Closed
11
Calls
$282K
Puts
–
Net Calls
+$282K
Net Calls Change
+$640K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$8.29M
2
TCM
Tekla Capital Management
Massachusetts
+$1.94M
3
BFA
BlackRock Fund Advisors
California
+$1.5M
4
BIT
BlackRock Institutional Trust
California
+$841K
5
BWCA
Brenner West Capital Advisors
New York
+$807K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$2.75M
2
NC
Nexthera Capital
New York
-$1.97M
3
WSA
Wall Street Associates
California
-$1.93M
4
BOS
Bingham Osborn & Scarborough
California
-$1.82M
5
CPH
C Partners Holding
Switzerland
-$973K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$46.2M – – –
GPP
2
Great Point Partners
Connecticut
$44M – – –
BWCA
3
Brenner West Capital Advisors
New York
$20.6M +$807K +52,188 +4%
BFA
4
BlackRock Fund Advisors
California
$14.4M +$1.5M +97,272 +13%
AllianceBernstein
5
AllianceBernstein
Tennessee
$12.4M +$570K +36,886 +5%
Vanguard Group
6
Vanguard Group
Pennsylvania
$11M +$398K +25,756 +4%
EMFAT
7
Emerald Mutual Fund Advisers Trust
Pennsylvania
$9.66M – – –
OTPPB
8
Ontario Teachers' Pension Plan Board
Ontario, Canada
$9.26M – – –
Millennium Management
9
Millennium Management
New York
$9.12M -$2.75M -177,526 -25%
AC
10
Armistice Capital
New York
$9.06M +$8.29M +536,000 New
EA
11
Emerald Advisers
Pennsylvania
$8.76M +$218K +14,071 +3%
BIT
12
BlackRock Institutional Trust
California
$5.9M +$841K +54,405 +18%
OM
13
Opaleye Management
Massachusetts
$4.82M +$541K +35,000 +14%
SFM
14
Sphera Funds Management
Israel
$4.56M – – –
State Street
15
State Street
Massachusetts
$4.36M +$235K +15,216 +6%
GPCM
16
Granite Point Capital Management
Massachusetts
$4.33M +$490K +31,700 +14%
Northern Trust
17
Northern Trust
Illinois
$3.37M +$107K +6,945 +4%
IBT
18
International Biotechnology Trust
United Kingdom
$3.13M +$2.86M +185,234 New
JP Morgan Chase
19
JP Morgan Chase
New York
$3.05M +$262K +16,934 +10%
Fidelity International
20
Fidelity International
Bermuda
$3.04M – – –
BBA
21
Baker Bros. Advisors
New York
$2.92M – – –
Point72 Asset Management
22
Point72 Asset Management
Connecticut
$2.78M +$525K +33,950 +26%
NC
23
Nexthera Capital
New York
$2.56M -$1.97M -127,070 -46%
CCMU
24
Cheyne Capital Management (UK)
United Kingdom
$2.45M +$464K +30,000 +26%
RPAM
25
Rhenman & Partners Asset Management
Sweden
$2.2M – – –
1
2 3 4

ADMS Hedge Fund Activity: Q4 2016 in Review

78 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q4 2016, worth a combined $273M — down 0.02% from $273M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ADMS and 10 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 28 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $8.29M. The largest seller was Millennium Management, cutting an estimated $2.75M.

  • 78 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q4 2016, down from 81 in Q3 2016.
  • Funds reported $273M of Adamas Pharmaceuticals stock for Q4 2016, down 0.02% quarter-over-quarter.
  • 10 funds opened new Adamas Pharmaceuticals positions in Q4 2016 and 11 closed out, a net change of -1 holder.
  • The largest Adamas Pharmaceuticals buyer in Q4 2016 was Armistice Capital, an estimated $8.29M added.
  • The largest Adamas Pharmaceuticals seller in Q4 2016 was Millennium Management, an estimated $2.75M sold.

Based on aggregated 13F filings for Q4 2016.